Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Betaxolol hydrochloride (SL 75212 HCl) 是一种 β1 肾上腺素受体阻断剂,可用于研究高血压和青光眼。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 266 | 现货 | ||
10 mg | ¥ 432 | 现货 | ||
50 mg | ¥ 783 | 现货 | ||
100 mg | ¥ 1,297 | 现货 | ||
200 mg | ¥ 1,696 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 475 | 现货 |
产品描述 | Betaxolol hydrochloride (SL 75212 HCl) is a cardioselective beta-blocker used in the treatment of hypertension.Betaxolol hydrochloride has not been linked to instances of clinically apparent drug induced liver injury. |
靶点活性 | β1-adrenoceptor:6 μM |
体外活性 | Betaxolol 的内含物可以部分阻止NMDA 和缺氧/ 葡萄糖引起的改变.在大鼠局部贫血前和再灌注损伤的时候腹腔注射Betaxolol可以有效减少钙网膜蛋白和ChAT免疫反应性的改变,并且可以阻止b波下降. |
体内活性 | 10 μM Betaxolol基本可以完全阻断谷氨酸酯诱导的LDH的释放。 100 μM Betaxolol能有效防止皮质组织中由缺氧引起的LDH的释放。Betaxolol能保护视网膜神经元。Betaxolol在β-肾上腺素受体激动剂无效时,会减弱NMDA诱导的45Ca2+流入。 |
细胞实验 | Dissociated cortical cells from 16–18-day-old fetal rats are grown, in 35 mm dishes, in DMEM supplemented with L-glutamine (4 mM), glucose (6 g/L), penicillin (100 U/mL), streptomycin (100 μg/mL) and 10% hormonal supplemented medium consisting of transferrin (1 mg/mL), insulin (250 μg/mL) putrescine (600 μM), sodium selenite (0.3 μM), progesterone (0.2 μM) and estradiol (0.1 pM) for 7 days in an atmosphere of 5% CO2/95% O2 at 37 °C. The cultures are then transferred to a culture medium which lacks the hormonal supplemented medium. L-glutamate is added to the medium and incubated for a further 4 hours under normoxic conditions. Betaxolol are added to the cultures at the same time as L-glutamate. In other experiments the cultures are subjected to anoxic conditions, 95% N2/5% CO2, for 5 hours at 37 °C. Betaxolol is added prior to anoxia. Reoxygenation is then achieved by replacing the cells in normoxic conditions (95% O2/5% CO2) for 3 hours. Cellular injury is assessed by measuring lactate dehydrogenase (LDH) release into the cell culture supernatant after hypoxia/reoxygenation or glutamate exposure. LDH activity is assayed spectrophotometrically by following NADH metabolism for 2 minutes at 340 nm.(Only for Reference) |
别名 | 盐酸倍他洛尔, SL75212, SL 75212 HCl, Betaxolol HCl |
分子量 | 343.89 |
分子式 | C18H30ClNO3 |
CAS No. | 63659-19-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200.6 mM
H2O: 29.08mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.9079 mL | 14.5395 mL | 29.0791 mL | 72.6977 mL |
5 mM | 0.5816 mL | 2.9079 mL | 5.8158 mL | 14.5395 mL | |
10 mM | 0.2908 mL | 1.454 mL | 2.9079 mL | 7.2698 mL | |
20 mM | 0.1454 mL | 0.727 mL | 1.454 mL | 3.6349 mL | |
DMSO | 50 mM | 0.0582 mL | 0.2908 mL | 0.5816 mL | 1.454 mL |
100 mM | 0.0291 mL | 0.1454 mL | 0.2908 mL | 0.727 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Betaxolol hydrochloride 63659-19-8 GPCR/G Protein Neuroscience Adrenergic Receptor Beta Receptor SL 75212 Inhibitor inhibit Betaxolol Hydrochloride 盐酸倍他洛尔 SL75212 SL 75212 HCl Betaxolol SL-75212 Betaxolol HCl inhibitor